reference/18785558

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18785558

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	5587
issn	1097-0142 0008-543X
issueIdentifier	22
pageRange	5580-5587
publicationName	Cancer
startingPage	5580
bibliographicCitation	Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 2012 Nov 15;118(22):5580–7. doi: 10.1002/cncr.27576. PMID: 22544579.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20397879da95d61705a54e8ba4e1ed95 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8e5d99076ae9c582c030d5b176d650d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04dfbf02c3a94b42d7a7146ca132991e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52b17d593ed4d715296b8aed57dfce63 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab5938400229f2b284c7250e3f84c42f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a68371cca1be251830b8465ed59ca456 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e6effc0f841ce34e98b8f504989e6d2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e9709b8f4b9737e9df916ac21fc1a9d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da3d4478c25180c6f34dea62bdecf23e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69137afcc4c208b95632efb68ec93575 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9adf9bc753c486ec3513482e4c3666a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc365a7a12a8636569ea34f510b1fd3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b317af9b460f15ff4b3170184bcbdfb1
date	2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/22544579 https://doi.org/10.1002/cncr.27576
isPartOf	https://portal.issn.org/resource/ISSN/1097-0142 https://portal.issn.org/resource/ISSN/0008-543X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
discusses	http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0328153 http://id.nlm.nih.gov/mesh/M0443627 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0009376
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D060046Q000009 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D008175Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005971Q000009 http://id.nlm.nih.gov/mesh/D016190Q000009 http://id.nlm.nih.gov/mesh/D016190Q000008 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D020533Q000009 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D020533Q000627 http://id.nlm.nih.gov/mesh/D006147Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000068437
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9062 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10516 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7627 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11071 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10602 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851

Total number of triples: 85.